Text size A A

At AGTC we are focused on genetic therapies that can restore visual function in patients with rare inherited conditions. In many instances, if left untreated these conditions can have a dramatic impact on patients’ daily activities and overall quality of life. Simple activities such as riding a bike, playing outside, and even the ability to recognize a loved one in a crowd, can be impossible for patients with rare blinding conditions. Our treatment candidates have the potential to dramatically improve visual function in patients with conditions where only palliative or no therapies exist today.

XLRS

X-Linked Retinoschisis
Program
Status: Phase 1/2
partner
Next milestone
Clinical Data

ACHM - CNGB3

Achromatopsia
Program
Status: Phase 1/2
partner
Wholly Owned by AGTC
Next milestone
Clinical Data

ACHM - CNGA3

Achromatopsia
Program
Status: Phase 1/2
partner
Wholly Owned by AGTC
Next milestone
Clinical Data

XLRP

X-Linked Retinitis Pigmentosa
Program
Status: Phase 1/2
partner
Next milestone
Clinical Data

Bionic Sight

Optogenetics
Program
Status: IND Enabling
partner
Next milestone
File IND

AMD - Targets 1&2

Age-Related Macular Degeneration
Program
Status: Proof of Concept
partner
Wholly Owned by AGTC
Next milestone
Target Announcement
Visionary science for life changing cures.